Provided by Tiger Trade Technology Pte. Ltd.

VolitionRX

0.4356
-0.0137-3.05%
Volume:4.69M
Turnover:1.94M
Market Cap:5.95M
PE:-0.11
High:0.4506
Open:0.3934
Low:0.3775
Close:0.4493
52wk High:14.80
52wk Low:0.3269
Shares:13.65M
Float Shares:12.33M
Volume Ratio:0.06
T/O Rate:38.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8023
EPS(LYR):-4.3726
ROE:-730.06%
ROA:-142.94%
PB:-0.18
PE(LYR):-0.10

Loading ...

VolitionRx director Mickie Henshall steps down, won’t seek re-election

Reuters
·
May 16

VolitionRx publishes corporate deck outlining Nu.Q licensing strategy in cancer, sepsis diagnostics

Reuters
·
May 15

BRIEF-VolitionRX Limited Announces First Quarter 2026 Financial Results

Reuters
·
May 15

VolitionRX Q1 EPS $(0.97) Misses $(0.75) Estimate, Sales $985.076K Beat $426.600K Estimate

Benzinga Earnings
·
May 15

VolitionRX Q1 FY26 net loss widens 22% to $6.7 million; revenue more than doubles to $1 million

Reuters
·
May 15

VolitionRx schedules first-quarter earnings conference call and business update

Reuters
·
May 11

Press Release: VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update

Dow Jones
·
May 11

VolitionRx feline cancer blood test study shows 86% sensitivity at 97% specificity

Reuters
·
May 06

VolitionRX Announces Submission of Manuscript for Nu.q® Vet Cancer Test in Cats

THOMSON REUTERS
·
May 06

VolitionRx detects nucleosomes in sepsis patients using finger-prick lateral flow prototype study

Reuters
·
Apr 29

VolitionRx enacts 1-for-20 reverse stock split via charter amendment

Reuters
·
Apr 29

VolitionRx wins NYSE American approval of compliance plan, avoids immediate delisting

Reuters
·
Apr 23

VolitionRX Announces Acceptance of Compliance Plan by Nyse American

THOMSON REUTERS
·
Apr 23

VolitionRX Cut to Hold From Buy by D. Boral Capital

Dow Jones
·
Apr 20

VolitionRx downgraded to Hold from Buy at D. Boral Capital

TIPRANKS
·
Apr 20

VolitionRx effects 1-for-20 reverse stock split April 28

Reuters
·
Apr 18

VolitionRX Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Apr 03

VolitionRx price target lowered to $1 from $1.50 at H.C. Wainwright

TIPRANKS
·
Apr 03

VolitionRx shareholders approved reverse stock split authorization at special meeting

Reuters
·
Apr 02

VolitionRx publishes corporate presentation outlining Nu.Q licensing-led cancer and sepsis diagnostics strategy

Reuters
·
Apr 01